New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Abbvie, ADC, Apellis, Aruvant, Caribou, Cogent, CTI, Cytovia, GBT, Genentech, GT, Imago, Janssen, Keros, MEI, Morphosys, Oryzon, Roche, Ryvu, Sobi, Vincerx, Vor.
At the 2022 Annual Congress of the European Hematology Association, researchers from the Spanish National Cancer Institute reported how high levels of the RNA-binding protein hnRNP-K could lead to bone marrow failure.
Analysts have already started tagging Cogent Biosciences Inc.’s bezuclastinib as potentially best in class, after the company presented impressive, though early stage, data at the European Hematology Association Congress in Vienna demonstrating promising efficacy and a possibly differentiating safety profile for the selective KIT D816V inhibitor in advanced systemic mastocytosis.
Beigene Ltd. unveiled positive interim results from its Alpine phase III trial comparing its small-molecule BTK inhibitor, Brukinsa (zanubrutinib), to Abbvie Inc.’s Imbruvica (ibrutinib), lending validity to one of the company’s most important development programs.
Johnson & Johnson’s Janssen Cilag Ltd. pharma unit has phase III data from its project combining the oral blood cancer drug Imbruvica (ibrutinib) with its blockbuster rival, Venclexta (venetoclax), in chronic lymphocytic leukemia (CLL), which could give it an edge over competitors in the space.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association 2021 Virtual Congress, including: Celltrion, Crispr, Daiichi Sankyo, Debiopharm, Janssen, Kite, Omeros, TG, Vertex, X4.
Beigene Ltd. unveiled positive interim results from its Alpine phase III trial comparing its small-molecule BTK inhibitor, Brukinsa (zanubrutinib), to Abbvie Inc.’s Imbruvica (ibrutinib), lending validity to one of the company’s most important development programs.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association 2021 Virtual Congress, including: Abbvie, Acceleron, Agios, Alexion, Aptose, Autolus, Beigene, Bergenbio, Bluebird, BMS, Caelum, Celyad, Constellation, Curis, Editas, Equillium, Forma, Genentech, Global Blood, Imago, Imara, Immunicum, Keros, Menarini, Mustang, Novartis, Oryzon, Protagonist, Ryvu.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association's Annual Congress, including: ADC, Agios, Alx, Apellis, Aprea, Aptose, Astrazeneca, Autolus, Beigene, Bluebird, Constellation, Crispr, Editas, Forma, Imago, Imara, Geron, Keros, Kiadis, Omeros, Oryzon, Principia, Sierra Oncology, Takeda, TG, Tolero, Vertex, X4.
RSS
